Towards a cancer mission in Horizon Europe: recommendations

Anton Berns; Ulrik Ringborg; Julio E Celis; Manuel Heitor; Neil K Aaronson; Nancy Abou-Zeid; Hans-Olov Adami; Kathi Apostolidis; Michael Baumann; Alberto Bardelli; René Bernards; Yvonne Brandberg; Carlos Caldas; Fabien Calvo; Caroline Dive; Angelika Eggert; Alexander Eggermont; Carolina Espina; Frederik Falkenburg; Jérôme Foucaud; Douglas Hanahan; Ulrike Helbig; Bengt Jönsson; Mette Kalager; Sakari Karjalainen; Miklós Kásler; Pamela Kearns; Klas Kärre; Denis Lacombe; Francesco de Lorenzo; Françoise Meunier; Gerd Nettekoven; Simon Oberst; Péter Nagy; Thierry Philip; Richard Price; Joachim Schüz; Eric Solary; Peter Strang; Josep Tabernero; Emile Voest

doi:10.1002/1878-0261.12763

Towards a cancer mission in Horizon Europe: recommendations

Anton Berns, Ulrik Ringborg, Julio E Celis, Manuel Heitor, Neil K Aaronson, Nancy Abou-Zeid, Hans-Olov Adami, Kathi Apostolidis, Michael Baumann, Alberto Bardelli, René Bernards, Yvonne Brandberg, Carlos Caldas, Fabien Calvo, Caroline Dive, Angelika Eggert, Alexander Eggermont, Carolina Espina, Frederik Falkenburg, Jérôme FoucaudDouglas Hanahan, Ulrike Helbig, Bengt Jönsson, Mette Kalager, Sakari Karjalainen, Miklós Kásler, Pamela Kearns, Klas Kärre, Denis Lacombe, Francesco de Lorenzo, Françoise Meunier, Gerd Nettekoven, Simon Oberst, Péter Nagy, Thierry Philip, Richard Price, Joachim Schüz, Eric Solary, Peter Strang, Josep Tabernero, Emile Voest

Cancer and Genomic Sciences

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

213 Downloads (Pure)

Abstract

A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.

Original language	English
Pages (from-to)	1589-1615
Number of pages	27
Journal	Molecular Oncology
Volume	14
Issue number	8
DOIs	https://doi.org/10.1002/1878-0261.12763
Publication status	Published - 4 Aug 2020

Bibliographical note

Funding Information:
We want to thank Christina von Gertten, coordinator of the EACS, for expert assistance during the preparation of the manuscript. We also like to thank the three EACS Committees that contributed with expert advice: Outcomes Research (Mette Kalager, chair, Hans-Olov Adami, Karen Steindorf, Paul Dickman, Pernilla Lagergren), Survivorship Research (Francoise Meunier, chair, Francesco de Lorenzo, Pernilla Lagergren, Mark Lawler, Francesco Saverio Mennini, Sarunas Narbutas) and Health Economics (Bengt J?nsson, chair; Michael Schlander, Wim H van Harten, Richard Sullivan, Nils Wilking). Their final reports will be submitted shortly for publication. We are also indebted to Claudio Lombardo for helpful suggestions, and Maria Papatriantafyllou for expert advice during the preparation of the manuscript. The financial support from the Foundation ARC, Paris, and the German Cancer Aid, Bonn, is also much appreciated.

Publisher Copyright:
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.

Keywords

European healthcare systems
cancer mission
cancer research/care/prevention continuum
comprehensive cancer centres
patient empowerment
science policy

ASJC Scopus subject areas

Molecular Medicine
Genetics
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/1878-0261.12763Licence: Creative Commons: Attribution (CC BY)

BernsA2020Towards
Berns, A., Ringborg, U., Celis, J.E., Heitor, M., Aaronson, N.K., Abou‐Zeid, N., Adami, H.‐O., Apostolidis, K., Baumann, M., Bardelli, A., Bernards, R., Brandberg, Y., Caldas, C., Calvo, F., Dive, C., Eggert, A., Eggermont, A., Espina, C., Falkenburg, F., Foucaud, J., Hanahan, D., Helbig, U., Jönsson, B., Kalager, M., Karjalainen, S., Kásler, M., Kearns, P., Kärre, K., Lacombe, D., de Lorenzo, F., Meunier, F., Nettekoven, G., Oberst, S., Nagy, P., Philip, T., Price, R., Schüz, J., Solary, E., Strang, P., Tabernero, J. and Voest, E. (2020), Towards a cancer mission in Horizon Europe: recommendations. Mol Oncol, 14: 1589-1615. https://doi.org/10.1002/1878-0261.12763
Final published version, 1.34 MBLicence: Creative Commons: Attribution (CC BY)

Cite this

Berns, A., Ringborg, U., Celis, J. E., Heitor, M., Aaronson, N. K., Abou-Zeid, N., Adami, H.-O., Apostolidis, K., Baumann, M., Bardelli, A., Bernards, R., Brandberg, Y., Caldas, C., Calvo, F., Dive, C., Eggert, A., Eggermont, A., Espina, C., Falkenburg, F., ... Voest, E. (2020). Towards a cancer mission in Horizon Europe: recommendations. Molecular Oncology, 14(8), 1589-1615. https://doi.org/10.1002/1878-0261.12763

@article{df9b570053f04434a294959f2a1482c9,

title = "Towards a cancer mission in Horizon Europe: recommendations",

abstract = "A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.",

keywords = "European healthcare systems, cancer mission, cancer research/care/prevention continuum, comprehensive cancer centres, patient empowerment, science policy",

author = "Anton Berns and Ulrik Ringborg and Celis, {Julio E} and Manuel Heitor and Aaronson, {Neil K} and Nancy Abou-Zeid and Hans-Olov Adami and Kathi Apostolidis and Michael Baumann and Alberto Bardelli and Ren{\'e} Bernards and Yvonne Brandberg and Carlos Caldas and Fabien Calvo and Caroline Dive and Angelika Eggert and Alexander Eggermont and Carolina Espina and Frederik Falkenburg and J{\'e}r{\^o}me Foucaud and Douglas Hanahan and Ulrike Helbig and Bengt J{\"o}nsson and Mette Kalager and Sakari Karjalainen and Mikl{\'o}s K{\'a}sler and Pamela Kearns and Klas K{\"a}rre and Denis Lacombe and {de Lorenzo}, Francesco and Fran{\c c}oise Meunier and Gerd Nettekoven and Simon Oberst and P{\'e}ter Nagy and Thierry Philip and Richard Price and Joachim Sch{\"u}z and Eric Solary and Peter Strang and Josep Tabernero and Emile Voest",

note = "Funding Information: We want to thank Christina von Gertten, coordinator of the EACS, for expert assistance during the preparation of the manuscript. We also like to thank the three EACS Committees that contributed with expert advice: Outcomes Research (Mette Kalager, chair, Hans-Olov Adami, Karen Steindorf, Paul Dickman, Pernilla Lagergren), Survivorship Research (Francoise Meunier, chair, Francesco de Lorenzo, Pernilla Lagergren, Mark Lawler, Francesco Saverio Mennini, Sarunas Narbutas) and Health Economics (Bengt J?nsson, chair; Michael Schlander, Wim H van Harten, Richard Sullivan, Nils Wilking). Their final reports will be submitted shortly for publication. We are also indebted to Claudio Lombardo for helpful suggestions, and Maria Papatriantafyllou for expert advice during the preparation of the manuscript. The financial support from the Foundation ARC, Paris, and the German Cancer Aid, Bonn, is also much appreciated. Publisher Copyright: {\textcopyright} 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2020",

month = aug,

day = "4",

doi = "10.1002/1878-0261.12763",

language = "English",

volume = "14",

pages = "1589--1615",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "Elsevier",

number = "8",

}

Berns, A, Ringborg, U, Celis, JE, Heitor, M, Aaronson, NK, Abou-Zeid, N, Adami, H-O, Apostolidis, K, Baumann, M, Bardelli, A, Bernards, R, Brandberg, Y, Caldas, C, Calvo, F, Dive, C, Eggert, A, Eggermont, A, Espina, C, Falkenburg, F, Foucaud, J, Hanahan, D, Helbig, U, Jönsson, B, Kalager, M, Karjalainen, S, Kásler, M, Kearns, P, Kärre, K, Lacombe, D, de Lorenzo, F, Meunier, F, Nettekoven, G, Oberst, S, Nagy, P, Philip, T, Price, R, Schüz, J, Solary, E, Strang, P, Tabernero, J & Voest, E 2020, 'Towards a cancer mission in Horizon Europe: recommendations', Molecular Oncology, vol. 14, no. 8, pp. 1589-1615. https://doi.org/10.1002/1878-0261.12763

TY - JOUR

T1 - Towards a cancer mission in Horizon Europe

T2 - recommendations

AU - Berns, Anton

AU - Ringborg, Ulrik

AU - Celis, Julio E

AU - Heitor, Manuel

AU - Aaronson, Neil K

AU - Abou-Zeid, Nancy

AU - Adami, Hans-Olov

AU - Apostolidis, Kathi

AU - Baumann, Michael

AU - Bardelli, Alberto

AU - Bernards, René

AU - Brandberg, Yvonne

AU - Caldas, Carlos

AU - Calvo, Fabien

AU - Dive, Caroline

AU - Eggert, Angelika

AU - Eggermont, Alexander

AU - Espina, Carolina

AU - Falkenburg, Frederik

AU - Foucaud, Jérôme

AU - Hanahan, Douglas

AU - Helbig, Ulrike

AU - Jönsson, Bengt

AU - Kalager, Mette

AU - Karjalainen, Sakari

AU - Kásler, Miklós

AU - Kearns, Pamela

AU - Kärre, Klas

AU - Lacombe, Denis

AU - de Lorenzo, Francesco

AU - Meunier, Françoise

AU - Nettekoven, Gerd

AU - Oberst, Simon

AU - Nagy, Péter

AU - Philip, Thierry

AU - Price, Richard

AU - Schüz, Joachim

AU - Solary, Eric

AU - Strang, Peter

AU - Tabernero, Josep

AU - Voest, Emile

N1 - Funding Information: We want to thank Christina von Gertten, coordinator of the EACS, for expert assistance during the preparation of the manuscript. We also like to thank the three EACS Committees that contributed with expert advice: Outcomes Research (Mette Kalager, chair, Hans-Olov Adami, Karen Steindorf, Paul Dickman, Pernilla Lagergren), Survivorship Research (Francoise Meunier, chair, Francesco de Lorenzo, Pernilla Lagergren, Mark Lawler, Francesco Saverio Mennini, Sarunas Narbutas) and Health Economics (Bengt J?nsson, chair; Michael Schlander, Wim H van Harten, Richard Sullivan, Nils Wilking). Their final reports will be submitted shortly for publication. We are also indebted to Claudio Lombardo for helpful suggestions, and Maria Papatriantafyllou for expert advice during the preparation of the manuscript. The financial support from the Foundation ARC, Paris, and the German Cancer Aid, Bonn, is also much appreciated. Publisher Copyright: © 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/8/4

Y1 - 2020/8/4

N2 - A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.

AB - A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.

KW - European healthcare systems

KW - cancer mission

KW - cancer research/care/prevention continuum

KW - comprehensive cancer centres

KW - patient empowerment

KW - science policy

UR - http://www.scopus.com/inward/record.url?scp=85088889362&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12763

DO - 10.1002/1878-0261.12763

M3 - Article

C2 - 32749074

SN - 1574-7891

VL - 14

SP - 1589

EP - 1615

JO - Molecular Oncology

JF - Molecular Oncology

IS - 8

ER -

Towards a cancer mission in Horizon Europe: recommendations

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this